Concepedia
Statistics
Publications
31
Citations
1.3K
H-Index
19
Active since
1994
Affiliations
Eli Lilly (United States)(Current)
The University of Texas at Austin
DuPont (United States)
University College Cork
Bristol-Myers Squibb (Germany)
Nicholas A. Magnus is an author at Eli Lilly (United States) specializing in medicinal chemistry, chemistry, and natural sciences.
Publications per year
1994–2017
Inhibition of Clinically Relevant Mutant Variants of HIV-1 by Quinazolinone Non-Nucleoside Reverse Transcriptase Inhibitors
Jeffrey W. Corbett, Soo S. Ko, James D. Rodgers et al. · Journal of Medicinal Chemistry · 2000 · 301 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +16
An Efficient Chiral Moderator Prepared from Inexpensive (+)-3-Carene: Synthesis of the HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitor DPC 963
Goss S. Kauffman, Gregory D. Harris, Roberta L. Dorow et al. · Organic Letters · 2000 · 193 citations
Pharmacy, Medicinal Chemistry, Pharmacology +11
Synthesis, Crystallization, and Biological Evaluation of an Orally Active Prodrug of Gemcitabine
David M. Bender, Anne H. Dantzig, William D. Diseroad et al. · Journal of Medicinal Chemistry · 2009 · 107 citations
Pharmacy, Medicinal Chemistry, Pharmacology +16
General Scope of 1,4-Diastereoselective Additions to a 2(3<i>H</i>)-Quinazolinone: Practical Preparation of HIV Therapeutics
Nicholas A. Magnus, Pat N. Confalone, Louis Storace et al. · The Journal of Organic Chemistry · 2002 · 54 citations
Pharmacy, Chemistry, Medicinal Chemistry +17
Design of Potent and Selective 2-Aminobenzimidazole-Based p38α MAP Kinase Inhibitors with Excellent in Vivo Efficacy
Alfonso de Dios, Chuan Shih, Beatriz López de Uralde et al. · Journal of Medicinal Chemistry · 2005 · 52 citations · Full text
Medicine, Medicinal Chemistry, Pharmacology +17
1–5 of 31